CAR-T cell therapy for hard-to-treat lupus in kids
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new type of cell therapy, called BCMA/CD70 CAR-T, for children with lupus that hasn't improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 5 years old
- You have been diagnosed with lupus and still have moderate to severe symptoms despite trying several standard treatments for at least 3 months
- Your lupus disease score (SLEDAI 2K) is 8 or higher
- Your heart, kidneys, liver, and lungs are working well enough for the treatment
- You have not had CAR-T therapy before, or you had CD19 CAR-T therapy before but it didn't work or stopped working
- You or your parent/guardian agree to join and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.